Professor of Medicine; Kern Wildenthal MD,PhD Distinguished Chair in Cardiology

UT Southwestern Medical School

Printed as of 4/26/2024

Disclosures

Personal Commercial (16)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott Diagnostics	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Amgen	Other - Data Monitoring Committee	Modest (< \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Beckman Coulter	Other - Endpoint committee	Significant (>= \$5,000)	Acute Coronary Syndromes
Cytokinetics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Data Safety Monitoring Board	Significant (>= \$5,000)	Other
Glaxo Smith Kline	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Jannsen	Data Safety Monitoring Board	Significant (>= \$5,000)	Acute Coronary Syndromes
Lianblo	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Data Safety Monitoring Board	Modest (< \$5,000)	Acute Coronary Syndromes Prevention
Novo Nordisk Inc.	Data Safety Monitoring Board	Significant (>= \$5,000)	General Cardiology
Regeneron	Data Safety Monitoring Board	Modest (< \$5,000)	Prevention
Roche Diagnostics	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Seimen's Health Care Diagnostics	Data Safety Monitoring Board	Significant (>= \$5,000)	Acute Coronary Syndromes
Varian Medical Systems	Data Safety Monitoring Board	Modest (< \$5,000)	Arrhythmias and Clinical EP
Verve Therapeutics	Data Safety Monitoring Board	Significant (>= \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/18/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attestation Agreement agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/18/2023

Embargo | Signed on 7/18/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/18/2023

ACC and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.